胞质5'-核苷酸酶1A自身抗体阳性包涵体肌炎的临床特征与预后
这项回顾性研究汇总欧洲多个包涵体肌炎注册库中311例患者数据,用ELISA检测抗胞质5'-核苷酸酶1A抗体,发现102例(33%)阳性。抗体阳性者调整后死亡风险更高(HR 1.89),起病时上肢近端无力频率更低,肌活检细胞色素氧化酶缺陷纤维增多更常见。提示该抗体状态可能区分出表型更重的包涵体肌炎亚型。
要点
- 抗NT5C1A抗体阳性率33%(102/311例包涵体肌炎患者)。
- 抗体阳性者调整后死亡风险升高(HR 1.89,95%CI 1.11–3.21,p=0.019)。
- 抗体阳性者肌活检细胞色素氧化酶缺陷纤维增多更常见(87% vs 72%)。
核心结论
- 抗胞质5'-核苷酸酶1A抗体阳性的包涵体肌炎患者调整后死亡风险更高,临床与病理特征存在差异。
- 按该抗体状态分层可能识别出表型更重的包涵体肌炎亚型。
研究设计与样本
- 回顾性研究,汇总欧洲多个包涵体肌炎注册库数据,共311例患者纳入分析。
- 用已建立的ELISA技术检测抗胞质5'-核苷酸酶1A抗体状态,按抗体状态分层比较。
- 生存和助行器需求分析采用Kaplan-Meier曲线和Cox比例风险回归。
主要发现
- 311例中102例(33%)抗胞质5'-核苷酸酶1A抗体阳性。
- 抗体阳性者调整后死亡风险更高(HR 1.89,95%CI 1.11–3.21,p=0.019)。
- 抗体阳性者起病时上肢近端无力频率更低(8% vs 23%,调整OR 0.29,95%CI 0.12–0.68,p=0.005)。
- 抗体阳性者肌活检细胞色素氧化酶缺陷纤维增多更常见(87% vs 72%,调整OR 2.80,95%CI 1.17–6.66,p=0.020)。
临床怎么用
- 对包涵体肌炎患者可检测抗胞质5'-核苷酸酶1A抗体,辅助识别死亡风险较高的亚型并加强随访。
- 抗体阳性且起病缺乏上肢近端无力者仍应结合肌活检细胞色素氧化酶缺陷纤维等结果综合评估。
局限性
- 为回顾性研究,数据来自注册库汇总,可能存在选择偏倚和未测量混杂。
- 原文未报告抗体检测与临床评估的具体时间关系及治疗对结局的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Autoantibodies directed against cytosolic 5'-nucleotidase 1A have been identified in many patients with inclusion body myositis. This retrospective study investigated the association between anticytosolic 5'-nucleotidase 1A antibody status and clinical, serological and histopathological features to explore the utility of this antibody to identify inclusion body myositis subgroups and to predict prognosis. MATERIALS AND METHODS: Data from various European inclusion body myositis registries were pooled. Anticytosolic 5'-nucleotidase 1A status was determined by an established ELISA technique. Cases were stratified according to antibody status and comparisons made. Survival and mobility aid requirement analyses were performed using Kaplan-Meier curves and Cox proportional hazards regression. RESULTS: Data from 311 patients were available for analysis; 102 (33%) had anticytosolic 5'-nucleotidase 1A antibodies. Antibody-positive patients had a higher adjusted mortality risk (HR 1.89, 95% CI 1.11 to 3.21, p=0.019), lower frequency of proximal upper limb weakness at disease onset (8% vs 23%, adjusted OR 0.29, 95% CI 0.12 to 0.68, p=0.005) and an increased prevalence of excess of cytochrome oxidase deficient fibres on muscle biopsy analysis (87% vs 72%, adjusted OR 2.80, 95% CI 1.17 to 6.66, p=0.020), compared with antibody-negative patients. INTERPRETATION: Differences were observed in clinical and histopathological features between anticytosolic 5'-nucleotidase 1A antibody positive and negative patients with inclusion body myositis, and antibody-positive patients had a higher adjusted mortality risk. Stratification of inclusion body myositis by anticytosolic 5'-nucleotidase 1A antibody status may be useful, potentially highlighting a distinct inclusion body myositis subtype with a more severe phenotype.
引用
- Lilleker JB, Rietveld A, Pye SR, et al. Cytosolic 5'-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis. Ann Rheum Dis. 2017. PMID: 28122761. doi:10.1136/annrheumdis-2016-210282
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。